Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: Cardinal Health is a leading provider of healthcare products and services, operating primarily through three segments: Healthcare Supply Chain Services, Clinical and Medical Products, and All Other. The company is currently executing a major restructuring of its segment operating structure and preparing for the planned spin-off of its clinical and medical products businesses into a new entity, CareFusion Corporation.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Mar 31, 2009 |
Three Months Ended Mar 31, 2008 |
Nine Months Ended Mar 31, 2009 |
Nine Months Ended Mar 31, 2008 |
|---|---|---|---|---|
| Revenue | $24,938.7 | $22,909.6 | $74,385.4 | $68,165.8 |
| Gross Margin | $1,401.7 | $1,467.8 | $4,182.6 | $4,164.7 |
| Operating Earnings | $496.3 | $576.5 | $1,460.5 | $1,585.5 |
| Net Earnings | $312.9 | $356.0 | $878.4 | $982.6 |
| Diluted EPS | $0.87 | $0.99 | $2.43 | $2.69 |
| Cash from Operating Activities | N/A | N/A | $739.6 | $1,269.8 |
| Cash and Equivalents (Balance) | $1,366.0 | N/A | N/A | N/A |
| Total Debt (Long-term + Current) | $3,671.1 | N/A | N/A | N/A |
Note: Total Debt calculated as Current portion of long-term obligations ($368.0M) + Long-term obligations ($3,303.1M) as of March 31, 2009.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 9% year-over-year for both the three and nine-month periods, driven by pharmaceutical price appreciation (8.7% index), increased volume from existing customers, and acquisitions. This growth was partially offset by customer losses and foreign exchange impacts.
- Profitability Decline: Operating earnings decreased 14% for the quarter and 8% for the nine-month period. Net earnings declined 12% and 11%, respectively.
- Margin Pressure: Gross margin decreased 5% for the quarter due to deferrals in hospital capital spending, product recalls (Alaris), and increased customer discounts. For the nine months, gross margin remained flat.
- Special Items: Special items increased significantly to $52.2 million for the quarter and $124.4 million for the nine months, primarily driven by restructuring charges ($48.1M and $112.1M, respectively) related to the planned spin-off and segment reorganization.
- Working Capital: Cash flow from operations decreased significantly ($740M vs $1.3B prior year) due to a $1.3 billion increase in inventories and an $870 million increase in trade receivables, offset by a $1.6 billion increase in accounts payable.
Guidance, Outlook, and Risks
- Planned Spin-Off: The company targets the summer of 2009 to complete the spin-off of CareFusion Corporation. This transaction is subject to regulatory approvals, tax rulings, and financing conditions. Estimated costs associated with the spin-off are $200 million to $230 million.
- Segment Outlook:
- Healthcare Supply Chain Services: Demand remains strong despite economic downturns, though bad debt expense has increased due to customer bankruptcies.
- Clinical and Medical Products: Results are negatively impacted by deferred hospital capital spending and a hold on shipping certain infusion products pending FDA corrective action plans. Management expects these headwinds to persist through the remainder of fiscal 2009.
- Regulatory and Legal Risks:
- FDA Consent Decree: The company is subject to an amended consent decree regarding infusion pump manufacturing standards. A $17.8 million reserve was recorded for corrective actions.
- IRS Audits: The IRS has proposed additional taxes totaling $598.1 million (excluding penalties) for tax years 2003-2005. The company intends to vigorously contest these adjustments.
- DEA Settlement: The company settled license suspension matters with the DEA for $34.0 million in the second quarter of fiscal 2009.
- Financial Covenants: In connection with the spin-off, the company amended its credit facilities to replace minimum net worth covenants with interest coverage (4-to-1) and leverage (3.25-to-1) ratios, effective upon consummation of the spin-off.
Investor Verification Checklist
- Spin-Off Timeline: Verify the status of the CareFusion spin-off conditions, specifically the IRS private letter ruling and credit rating requirements.
- Inventory Levels: Assess the $1.3 billion increase in inventory and its impact on future working capital needs and potential obsolescence risks.
- Bad Debt Exposure: Monitor the impact of the economic downturn on the Healthcare Supply Chain Services segment, specifically regarding the bankruptcy of regional chain customers.
- FDA Compliance: Track the resolution of the Alaris infusion pump corrective action plan and any potential further recalls or penalties.
- Tax Contingencies: Review the potential financial impact of the $598.1 million IRS proposed adjustment and the company's ability to defend the position.
- Restructuring Costs: Confirm the remaining estimated costs of $198 million for restructuring and spin-off activities.